Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. The Austrian Pediatric Oncology Group.

The prognostic significance of expression of myeloid-associated antigens in childhood acute lymphoblastic leukemia (myA+ALL) was evaluated. From 1984 to 1990, 251 children with immunologically verified ALL were treated in two prospective consecutive Austrian studies. Complete immunophenotyping was performed in 206 cases (82%). Out of these 175 cases were classified as B-cell precursor ALL, 31 cases as T-ALL. Expression of myeloid-associated antigens was demonstrated in 23 cases (13.1%) of childhood B-cell precursor ALL, particularly in immature (CD10 negative) forms (P < .0001), and in 1 case (3.2%) of T-ALL. CDw65 was expressed most frequently (12 cases), followed by CD13 and CD15 (5 cases each), CD33 (4 cases), and blood-group H (3 cases). Compared to myA- ALL prognosis of children with myA+ B-cell precursor ALL was poor, despite intensive multiagent chemotherapy according to BFM protocols. Remission rates were not impaired, but pEFS was 74.6% for myA- ALL, and only 37.8% for myA+ ALL (P = .0001). As demonstrated by multivariate analysis the expression of myeloid-associated antigens was the most important prognostic variable for EFS in B-cell precursor ALL, whether or not CD10 was expressed.

[1]  S. Raimondi,et al.  Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. , 1991, Blood.

[2]  E. Thiel,et al.  Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. , 1991, Leukemia.

[3]  K. Weinberg,et al.  Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. , 1991, The New England journal of medicine.

[4]  B. Komischke,et al.  [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies]. , 1990, Klinische Padiatrie.

[5]  C. Marosi,et al.  Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Dörken,et al.  CD Antigens 1989 , 1989, International journal of cancer.

[7]  J. Harbott,et al.  Phenotypic and genotypic heterogeneity in infant acute leukemia. II. Acute nonlymphoblastic leukemia. , 1989, Leukemia.

[8]  W. Hiddemann,et al.  Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. , 1988, Blood.

[9]  I Royston,et al.  Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. , 1987, The New England journal of medicine.

[10]  S. Stass,et al.  Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance , 1985 .

[11]  R. Dunstan,et al.  The origin of ABH antigens on human platelets. , 1985, Blood.

[12]  W. Aberer,et al.  M2, A novel myelomonocytic cell surface antigen and its distribution on leukemic cells , 1984, International journal of cancer.

[13]  K. Foon,et al.  Surface markers on leukemia and lymphoma cells: recent advances. , 1982, Blood.

[14]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[16]  F. Behm,et al.  Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy , 1990 .

[17]  G. Mueller,et al.  Childhood acute lymphoblastic leukemia: results of the Austrian Cooperative Study Group with the ALL A 84 protocol. , 1990, Medical and pediatric oncology.

[18]  E. Thiel,et al.  Incidence and clinical implications of acute hybrid leukemia in childhood. , 1990, Haematology and blood transfusion.

[19]  J. Reuben,et al.  Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. , 1989, Leukemia.

[20]  M. Schrappe,et al.  Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. , 1987, Haematology and blood transfusion.